A review of oral cannabinoids and medical marijuana for chemotherapy-induced nausea and vomiting: a focus or pharmacodynamics

Cancer Chemotherapy and Pharmacology 80, 441-449

DOI: 10.1007/s00280-017-3387-5

Citation Report

#	Article	IF	CITATIONS
1	Understanding the Impact of National and State Medical Marijuana Policies on Adolescents. Current Addiction Reports, 2018, 5, 93-101.	3.4	13
2	Zebrafish models relevant to studying central opioid and endocannabinoid systems. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 86, 301-312.	4.8	48
3	Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and î"9-Tetrahydrocannabinol. Neuropsychopharmacology, 2018, 43, 142-154.	5.4	178
4	A Budding Cannabis Cottage-Industry has set the stage for an Impending Public Health Crisis. Pharmaceutical Regulatory Affairs: Open Access, 2018, 07, .	0.2	O
5	A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms. CNS Drugs, 2018, 32, 1113-1129.	5.9	14
6	Medical marijuana in the United States: Historical perspectives, legal considerations, and professional obligations of the pharmacist. JACCP Journal of the American College of Clinical Pharmacy, 2018, 1, e9.	1.0	1
7	Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long history. Journal of Ethnopharmacology, 2018, 227, 300-315.	4.1	378
8	The ameliorative effect of hemp seed hexane extracts on the Propionibacterium acnes-induced inflammation and lipogenesis in sebocytes. PLoS ONE, 2018, 13, e0202933.	2.5	37
9	Synthetic cannabinoids are substrates and inhibitors of multiple drug-metabolizing enzymes. Archives of Pharmacal Research, 2018, 41, 691-710.	6.3	43
10	The Pediatrician and Marijuana. Advances in Pediatrics, 2018, 65, 159-171.	1.4	2
11	Irinotecan and Δ9-Tetrahydrocannabinol Interactions in Rat Liver: A Preliminary Evaluation Using Biochemical and Genotoxicity Markers. Molecules, 2018, 23, 1332.	3.8	11
12	Cannabinoid pharmacology and therapy in gut disorders. Biochemical Pharmacology, 2018, 157, 134-147.	4.4	38
13	New approaches and challenges to targeting the endocannabinoid system. Nature Reviews Drug Discovery, 2018, 17, 623-639.	46.4	346
14	Utilization of medicinal cannabis for pain by individuals with spinal cord injury. Spinal Cord Series and Cases, 2019, 5, 66.	0.6	8
15	Cannabis and Cannabinoids: Kinetics and Interactions. American Journal of Medicine, 2019, 132, 1266-1270.	1.5	62
16			
10	Effect of irinotecan on the tongue mucosa of juvenile male albino rat at adulthood. International Journal of Experimental Pathology, 2019, 100, 244-252.	1.3	6
17	Effect of irinotecan on the tongue mucosa of juvenile male albino rat at adulthood. International Journal of Experimental Pathology, 2019, 100, 244-252. Effect of electrical stimulation for chemotherapy-induced nausea and vomiting in patients with liver cancer. Medicine (United States), 2019, 98, e15255.	1.3	2

#	Article	IF	CITATIONS
19	Medications development for food-based and drug use disorders. Advances in Pharmacology, 2019, 86, 197-236.	2.0	1
20	Pharmacokinetics of oral and intravenous cannabidiol and its antidepressant-like effects in chronic mild stress mouse model. Environmental Toxicology and Pharmacology, 2019, 70, 103202.	4.0	67
21	DNA Damaging Effects, Oxidative Stress Responses and Cholinesterase Activity in Blood and Brain of Wistar Rats Exposed to î"9-Tetrahydrocannabinol. Molecules, 2019, 24, 1560.	3.8	12
22	Development and validation of an assay to measure cannabidiol and Δ9-tetrahydrocannabinol in human EDTA plasma by UHPLC-MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1112, 56-60.	2.3	14
24	The protective effects of \hat{l} "9-tetrahydrocannabinol against inflammation and oxidative stress in rat liver with fructose-induced hyperinsulinemia. Journal of Pharmacy and Pharmacology, 2019, 71, 408-416.	2.4	8
25	Emerging structural biology of lipid G proteinâ€coupled receptors. Protein Science, 2019, 28, 292-304.	7.6	46
26	Cannabis for musculoskeletal pain and arthritis: Evidence is needed. Joint Bone Spine, 2019, 86, 1-3.	1.6	8
27	Modelâ€based analysis on systemic availability of coâ€administered cannabinoids after controlled vaporised administration. Internal Medicine Journal, 2020, 50, 846-853.	0.8	11
28	Living with a Hope of Survival Is Challenged by a Lack of Clinical Evidence: An Interview Study among Cancer Patients Using Cannabis-Based Medicine. Journal of Palliative Medicine, 2020, 23, 1090-1093.	1.1	11
29	Rural-urban differences in cannabis detected in fatally injured drivers in the United States. Preventive Medicine, 2020, 132, 105975.	3.4	12
30	Increasing cannabis use and importance as an environmental contaminant mixture and associated risks to exposed biota: A review. Critical Reviews in Environmental Science and Technology, 2022, 52, 203-239.	12.8	5
31	Cannabinoids, Inner Ear, Hearing, and Tinnitus: A Neuroimmunological Perspective. Frontiers in Neurology, 2020, 11, 505995.	2.4	9
32	High Doses of Δ9-Tetrahydrocannabinol Might Impair Irinotecan Chemotherapy: A Review of Potentially Harmful Interactions. Clinical Drug Investigation, 2020, 40, 775-787.	2.2	2
33	Cannabinoids for Pain Control During Medical Abortion. Obstetrics and Gynecology, 2020, 135, 1289-1295.	2.4	6
34	Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs. Biomolecules, 2020, 10, 855.	4.0	24
35	Oral Administration of Cannabis and î"-9-tetrahydrocannabinol (THC) Preparations: A Systematic Review. Medicina (Lithuania), 2020, 56, 309.	2.0	38
36	A Guide to Targeting the Endocannabinoid System in Drug Design. International Journal of Molecular Sciences, 2020, 21, 2778.	4.1	79
37	Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies. EPMA Journal, 2020, 11, 217-250.	6.1	25

3

#	Article	IF	CITATIONS
38	Role of Cannabis and Its Derivatives in Gastrointestinal and Hepatic Disease. Gastroenterology, 2020, 159, 62-80.	1.3	29
39	Exploring the Use of State Medical Cannabis Legislation as a Proxy for Medical Cannabis Use Among Patients Receiving Chemotherapy. Current Treatment Options in Oncology, 2021, 22, 1.	3.0	5
40	Practical Recommendations for the Use of Medical Cannabis. , 2021, , 153-165.		0
41	Cannabis sativa L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment. International Journal of Molecular Sciences, 2021, 22, 778.	4.1	49
42	Use of cannabinoids for the treatment of patients with post-traumatic stress disorder. Journal of Basic and Clinical Physiology and Pharmacology, 2022, 33, 121-132.	1.3	5
43	A Quality-of-Life Evaluation Study Assessing Health-Related Quality of Life in Patients Receiving Medicinal Cannabis (the QUEST Initiative): Protocol for a Longitudinal Observational Study. JMIR Research Protocols, 2021, 10, e32327.	1.0	1
44	Cannabinoids and Cancer. Cancers, 2021, 13, 4458.	3.7	1
45	Dronabinol (Marinol®)., 2021,, 105-107.		2
46	Cannabis sativa subsp. sativa's pharmacological properties and health effects: A scoping review of current evidence. PLoS ONE, 2021, 16, e0245471.	2.5	18
47	The effect of oral î"-9-tetrahydrocannabinol on the minimal alveolar concentration of sevoflurane. European Journal of Anaesthesiology, 2021, 38, 58-63.	1.7	5
48	Pharmacological Approaches to Diabetic Gastroparesis: A systematic review of randomised clinical trials. Sultan Qaboos University Medical Journal, 2019, 19, 291.	1.0	6
49	Pharmacotherapeutic Considerations for Use of Cannabinoids to Relieve Symptoms of Nausea and Vomiting Induced by Chemotherapy. Folia Medica, 2020, 62, 668-678.	0.5	3
50	Carbon-silicon switch led to the discovery of novel synthetic cannabinoids with therapeutic effects in a mouse model of multiple sclerosis. European Journal of Medicinal Chemistry, 2021, 226, 113878.	5.5	2
51	Chemotherapy Induced Nausea and Vomiting. , 2019, , 1007-1045.		0
52	Cannabis : enjeux et risques en médecine de la douleur. Douleur Et Analgesie, 2019, 32, 73-78.	0.1	0
53	Chapter 19: Nausea and Vomiting. , 2020, , .		0
54	KomplementÃ ¤ medizin. , 2022, , 136-145.		0
55	Alterações no paladar advindos de quimioterapia convencional. Research, Society and Development, 2021, 10, e589101422467.	0.1	0

#	ARTICLE	IF	CITATIONS
56	The endocannabinoid system impacts seizures in a mouse model of Dravet syndrome. Neuropharmacology, 2022, 205, 108897.	4.1	9
57	Distinct Binding Mechanisms for Allosteric Sodium Ion in Cannabinoid Receptors. ACS Chemical Neuroscience, 2022, 13, 379-389.	3.5	15
58	A Comprehensive Review on the Techniques for Extraction of Bioactive Compounds from Medicinal Cannabis. Molecules, 2022, 27, 604.	3.8	48
59	Considerations for Cannabinoids in Perioperative Care by Anesthesiologists. Journal of Clinical Medicine, 2022, 11, 558.	2.4	7
60	Applications of Cannabinoids in Neuropathic Pain : An updated review. Critical Reviews in Therapeutic Drug Carrier Systems, 2022, , .	2.2	0
61	Neurological complications of steroids and of supportive care. , 2022, , 553-561.		1
62	Efficacy of medicinal cannabis for appetite-related symptoms in people with cancer: A systematic review. Palliative Medicine, 2022, 36, 912-927.	3.1	13
63	Anti-Microbial Activity of Phytocannabinoids and Endocannabinoids in the Light of Their Physiological and Pathophysiological Roles. Biomedicines, 2022, 10, 631.	3.2	17
64	A broader view on deriving a reference dose for THC traces in foods. Critical Reviews in Toxicology, 2021, 51, 695-722.	3.9	4
65	Role of Cannabinoids in Various Diseases: A Review. Current Pharmaceutical Biotechnology, 2022, 23, 1346-1358.	1.6	6
68	Chronic Administration of Cannabinoid Receptor 2 Agonist (JWH-133) Increases Ectopic Ovarian Tumor Growth and Endocannabinoids (Anandamide and 2-Arachidonoyl Glycerol) Levels in Immunocompromised SCID Female Mice. Frontiers in Pharmacology, 2022, 13, 823132.	3.5	1
69	Cannabinoid receptor 1 antagonist genistein attenuates marijuana-induced vascular inflammation. Cell, 2022, 185 , 1676 - 1693 .e23.	28.9	40
70	Metabolic engineering of microorganisms for the production of carotenoids, flavonoids, and functional polysaccharides., 2022,, 281-306.		0
72	Differentiating Cannabis Products: Drugs, Food, and Supplements. Frontiers in Pharmacology, 0, 13, .	3.5	11
74	Assessment of dependence potential and abuse liability of î"8-tetrahydrocannabinol in mice. Drug and Alcohol Dependence, 2022, 240, 109640.	3.2	6
7 5	Raising awareness: The implementation of medical cannabis and psychedelics used as an adjunct to standard therapy in the treatment of advanced metastatic breast cancer. Drug Science, Policy and Law, 2022, 8, 205032452211143.	1.3	0
76	Therapeutic Effects of Medicinal Cannabinoids on the Gastrointestinal System in Pediatric Patients: A Systematic Review. Cannabis and Cannabinoid Research, 0, , .	2.9	0
77	Cannabinoids: Legal aspects, pharmacology, phytochemistry, probable targets from biological system, and therapeutic potential. Asian Journal of Pharmaceutical Research and Health Care, 2022, 14, 127.	0.1	O

#	Article	IF	CITATIONS
78	A Systematic Review of Medical Cannabinoids Dosing in Human. Clinical Therapeutics, 2022, 44, e39-e58.	2.5	4
79	Comparison of the Cannabinoid and Terpene Profiles in Commercial Cannabis from Natural and Artificial Cultivation. Molecules, 2023, 28, 833.	3.8	6
80	Understanding the suitability of parametric modeling techniques in detecting the changes in the HRV signals acquired from cannabis consuming and nonconsuming Indian paddy-field workers., 2023,, 61-85.		0
81	Cannabinoids in traumatic brain injury and related neuropathologies: preclinical and clinical research on endogenous, plant-derived, and synthetic compounds. Journal of Neuroinflammation, 2023, 20, .	7.2	5
82	Role of Cannabis sativa L. in the Cosmetic Industry. Advances in Medical Diagnosis, Treatment, and Care, 2023, , 81-100.	0.1	0
83	Cannabis sativa. Advances in Medical Diagnosis, Treatment, and Care, 2023, , 1-28.	0.1	0
84	Cannabinoids and Multiple Sclerosis: A Critical Analysis of Therapeutic Potentials and Safety Concerns. Pharmaceutics, 2023, 15, 1151.	4.5	1
85	Risk Factors of Oral Cancer: Identification and Mechanism of Prevention. , 2023, , 1-29.		O
86	Cannabis Pharmacogenomics: A Path to Personalized Medicine. Current Issues in Molecular Biology, 2023, 45, 3479-3514.	2.4	2
87	Cannabis Sativa in Phytotherapy: Reappraisal of Therapeutic Potential and Regulatory Aspects. Current Pharmaceutical Biotechnology, 2023, 24, .	1.6	0
88	Tumor growth and the endocannabinoid system: Investigating CB2 agonists., 2023,, 529-541.		0
89	Pharmacological aspects of cannabinoids. Ûžno-Rossijskij žurnal TerapevtiÄeskoj Praktiki, 2023, 4, 27-35.	0.3	0
91	An overview of phytochemical constituents and pharmacological implications of Cannabis sativa L Journal of Herbal Medicine, 2023, 42, 100798.	2.0	0
92	Cannabinoid-Associated Hyperemesis Syndrome Treated With Dronabinol: Killing a Poison With the Poison. Cureus, 2023, , .	0.5	0
93	Drug interactions of tetrahydrocannabinol and cannabidiol in cannabinoid drugs. Deutsches Ärzteblatt International, 0, , .	0.9	1
94	Toll-like receptor signalling as a cannabinoid target. Biochemical Pharmacology, 2024, 222, 116082.	4.4	0
95	A randomised, placebo-controlled, double blind, crossover trial on the effect of a 20:1 cannabidiol: î"9-tetrahydrocannabinol medical cannabis product on neurocognition, attention, and mood. European Neuropsychopharmacology, 2024, 82, 35-43.	0.7	0
96	Discovery of Latent Cannabichromene Cyclase Activity in Marine Bacterial Flavoenzymes. ACS Synthetic Biology, 2024, 13, 1343-1354.	3.8	0